Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMorton, J.I.-
dc.contributor.authorMcDonald, S.P.-
dc.contributor.authorSalim, A.-
dc.contributor.authorLiew, D.-
dc.contributor.authorShaw, J.E.-
dc.contributor.authorMagliano, D.J.-
dc.identifier.citationDiabetes Care, 2021; 44(7):1515-1523-
dc.description.abstractObjective This study sought to examine the effects of two diabetes prevention approaches and of widespread use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) among people with diabetes on the future incidence of diabetes-related end-stage kidney disease (ESKD-D).<h4>Research design and methods</h4>We developed a life table model to project the incidence of ESKD-D for type 2 diabetes in Australia until 2040. We projected incident ESKD-D under three separate scenarios: a large-scale lifestyle modification program for diabetes prevention; a population-wide sugar-sweetened beverage tax for diabetes prevention; and widespread use of SGLT2is among people with diabetes.<h4>Results</h4>Assuming current trends, we projected that the annual incidence of ESKD-D will increase from 3.7 per 100,000 of the general population in 2014 to 5.7 by 2040. Incorporating the diabetes prevention approaches, we projected that the annual incidence of ESKD-D will be between 5.2 and 5.5 per 100,000 by 2040. When we modeled scenarios in which 50% and 70% of eligible people with diabetes were prescribed an SGLT2i, the annual incidence of ESKD-D by 2040 was projected to be 4.7 and 4.3 per 100,000, respectively. SGLT2is were projected to reduce the total number of incident ESKD-D cases between 2020 and 2040 by 12-21% compared with current trends, whereas diabetes prevention reduced cases by 1-3%.<h4>Conclusions</h4>It is likely that the number of people developing ESKD-D will increase over the coming decades, although widespread SGLT2i use will be effective at limiting this increase. Diabetes prevention will be crucial to prevent an ever-increasing burden of diabetes complications.-
dc.description.statementofresponsibilityJedidiah I. Morton, Stephen P. McDonald, Agus Salim, Danny Liew, Jonathan E. Shaw and Dianna J. Magliano-
dc.publisherAmerican Diabetes Association-
dc.rights© 2021 by the American Diabetes Association-
dc.subjectKidney Failure, Chronic-
dc.subjectDiabetes Mellitus, Type 2-
dc.titleProjecting the incidence of type 2 diabetes-related end-stage kidney disease until 2040: a comparison between the effects of diabetes prevention and the effects of diabetes treatment-
dc.typeJournal article-
dc.identifier.orcidMcDonald, S.P. [0000-0001-6103-1386]-
dc.identifier.orcidLiew, D. [0000-0002-0131-623X]-
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.